Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine. by Goodwin, G, Boyer, P, Emsley, R, Rouillon, F, de Bodinat, C

Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine by Goodwin, G, Boyer, P, Emsley, R, Rouillon, F, De Bodinat, C

The cognitive science of religion: past, present, and possible futures by White, C, Barrett, JL, Boyer, P, Lawson, ET, McCauley, RN, Whitehouse, H

Antidepressant effect in older depressed patients: the lessons of two agomelatine trials by Goodwin, G, Thomas, P, Heun, R, Boyer, P, Picarel-Blanchot, F, de Bodinat, C

The effects of COVID-19 on European healthcare provision for working-age adults with major depressive disorder by Wong, WLE, Sually, D, Hidalgo-Mazzei, D, Quoidbach, V, Simon, J, Boyer, P, Strawbridge, R, Young, AH

Comparing pollen and archaeobotanical data for Chalcolithic cereal agriculture at Çatalhöyük, Turkey by Eastwood, W, Fairbairn, A, Stroud, E, Roberts, N, Lamb, H, Yiğitbaşıoğlu, H, Şenkul, Ç, Moss, A, Turner, R, Boyer, P